AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 191 min read$TEVA

Lippman Evan sold $680K of TEVA

Lippman Evan (EVP, Business Development) sold 18,600 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $36.57 ($0.68M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lippman Evan
Published Aug 19, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 8:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TEVA
Bearish
medium confidence
Mentioned
$TEVA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVABearishLow
01

Why it matters

The disclosed sale reduces the insider's ownership, which may be interpreted as a lack of confidence, but could also be a pre-planned liquidity event.

02

Market read

Provides fresh insider transaction data for TEVA, useful for short-term traders.

03

What to watch

Potential upcoming corporate actions or earnings that may affect insider behavior.

Relevance 4/10Novelty 6/10Timing: filing date 2026-08-19

Background

Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$TEVABearishMedium confidence
Context

EVan Lippman, EVP of Business Development, sold 18,600 shares for $680,291 via a 10b5-1 plan, reducing his stake to 25,591 shares.

Expected impact

Possible modest downside pressure in the next trading session.

Evidence & confidence

The sale size (~$0.68M) is material for an insider but not large enough to drive a major move; market may react cautiously.

Market effects

Sector

Minimal impact on the broader pharmaceutical sector.

Regional

Limited to markets tracking TEVA shares.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5-1 plan and not indicative of insider concern.

Key entities

  • Officer
    Lippman Evan

    EVP, Business Development at TEVA

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

SEP 4
$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

investing.com2 min
SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min